ZJYL · Jin Medical International Ltd.

This filing confirms Jin Medical’s restoration of compliance with Nasdaq’s minimum bid price requirement, a critical listing standard that, if unmet, could trigger delisting proceedings. The Company achieved compliance by sustaining a $1.00+ closing bid price for over ten consecutive business days — a threshold explicitly cited in Nasdaq’s written notification. While the filing does not disclose the specific trading period or share price trajectory leading to compliance, the confirmation itself resolves an active listing deficiency previously disclosed in prior communications (not included in this filing). For investors, this eliminates near-term regulatory risk associated with potential delisting, which could impair liquidity, index eligibility, and institutional investor participation. However, the filing contains no forward-looking metrics on financial performance, capital structure, or operational progress — only the procedural outcome of regaining compliance. The absence of earnings data, balance sheet updates, or strategic milestones limits the event’s materiality to listing status maintenance rather than fundamental business advancement. As a foreign private issuer filing on Form 6-K, Jin Medical is not subject to the same disclosure thresholds as U.S. domestic issuers, and this notice serves primarily as a regulatory update rather than an operational catalyst.